Lacoste D, Caron S, Bélanger A, Labrie F
MRC Group in Molecular Endocrinology, Laval University Medical Center, Quebec, Canada.
J Steroid Biochem. 1989 Aug;33(2):233-42. doi: 10.1016/0022-4731(89)90299-9.
Adult male mongrel dogs were treated with the LHRH agonist [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination for 21 days before measurement of steroid levels in the testes, prostate, adrenals and serum. Ketoconazole alone caused a marked stimulation of the intra-testicular concentration of pregnenolone, 17OH-pregnenolone, progesterone and 17OH-progesterone with no or little change of androstenedione, testosterone and dihydrotestosterone. Aminoglutethimide caused a 30-95% inhibition in the concentration of all steroids in the tests while treatment with the LHRH agonist caused a near complete inhibition of all testicular steroids. When administered concomitantly with the LHRH agonist, ketoconazole partly prevented the inhibitory effect of the LHRH agonist on testicular steroid levels. Serum levels of dehydroepiandrosterone, androst-5-ene-3 beta,17 beta-diol, androstenedione and androstane-3 alpha, 17 beta-diol were 75 to 95% inhibited by the LHRH agonist while serum testosterone and dihydrotestosterone concentrations were reduced below detection limits by the same treatment. Moreover, treatment with the LHRH agonist caused a 70-95% reduction in the intraprostatic concentration of testosterone and dihydrotestosterone in all the groups although maximal effect was observed when the LHRH agonist was combined with any of the three other agents. The present data show that while treatment with ketoconazole, aminoglutethimide or Flutamide alone has only partial inhibitory effects on androgen levels, combination with an LHRH agonist provides maximal inhibition. In addition to its direct blockade of the androgen receptor, some of the effect of Flutamide could be related to its blockade of testicular 3 beta-hydroxy-steroid dehydrogenase activity.
成年雄性杂种犬在测量睾丸、前列腺、肾上腺和血清中的类固醇水平前21天,单独或联合使用促黄体生成素释放激素(LHRH)激动剂[D-色氨酸6,去甘氨酰胺10(2)]LHRH乙酰胺、氨鲁米特、酮康唑或氟他胺进行治疗。单独使用酮康唑可显著刺激睾丸内孕烯醇酮、17-羟孕烯醇酮、孕酮和17-羟孕酮的浓度,而雄烯二酮、睾酮和双氢睾酮无变化或仅有轻微变化。氨鲁米特可使睾丸中所有类固醇的浓度降低30%-95%,而用LHRH激动剂治疗可使所有睾丸类固醇几乎完全受到抑制。当与LHRH激动剂同时给药时,酮康唑部分阻止了LHRH激动剂对睾丸类固醇水平的抑制作用。LHRH激动剂可使血清脱氢表雄酮、雄烯-5-烯-3β,17β-二醇、雄烯二酮和雄烷-3α,17β-二醇的水平降低75%-95%,而血清睾酮和双氢睾酮浓度则因相同治疗降低至检测限以下。此外,LHRH激动剂治疗使所有组前列腺内睾酮和双氢睾酮的浓度降低70%-95%,尽管当LHRH激动剂与其他三种药物中的任何一种联合使用时观察到最大效果。目前的数据表明,虽然单独使用酮康唑、氨鲁米特或氟他胺对雄激素水平只有部分抑制作用,但与LHRH激动剂联合使用可提供最大抑制作用。除了直接阻断雄激素受体外,氟他胺的一些作用可能与其阻断睾丸3β-羟基类固醇脱氢酶活性有关。